Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Akebia Therapeutics
Biotech
Akebia promises $12M for Q32’s rare kidney disease candidate
Akebia has struck a deal for Q32's complement inhibitor ADX-097, bagging an asset that forms the centerpiece of its new rare kidney disease pipeline.
Nick Paul Taylor
Dec 1, 2025 9:45pm
Akebia says FDA staffing issues are delaying appeal process
Feb 21, 2023 10:45am
Akebia is taking the fight to the FDA months after rejection
Nov 4, 2022 12:02pm
Akebia's anemia drug just misses in a COVID-19 trial
Aug 5, 2022 10:14am
After dispute, Otsuka pays Akebia $55M to exit anemia pill pacts
Jul 1, 2022 8:15am
Fierce Biotech launches layoff tracker—Chutes and Ladders
Apr 8, 2022 9:30am
